Publications
Specialty
Search
Oncology, Journal of Clinical Pathways
09/17/2024
Jamie Chaft, MD, discusses the 5-year follow-up data from the IMpower010 trial which showed atezolizumab continued to provide greater improvement to disease-free survival than best supportive care for patients with resectable early-stage non-small cell lung cancer, regardless of disease stage or regional lymph node status.
EP Lab Digest
09/17/2024
iCardio.ai is announcing a collaboration with Abbott to develop artificial intelligence applications for its imaging devices.
Oncology
09/17/2024
Gabriela Hobbs, MD, provides an overview of the latest strategies and updates regarding the management and treatment of patients with polycythemia vera.
Oncology
09/17/2024
On September 17, 2024, the FDA approved ribociclib with an aromatase inhibitor as well as a ribociclib and letrozole co-pack for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative stage II and III early breast cancer.
First Report Managed Care
09/17/2024
Discover how Kindred Hospitals, a national network of long-term acute care hospitals (LTACHs), are improving patient outcomes and reducing health care costs for complex wound patients through their advanced wound care program.
Today's Wound Clinic, Wound Care
09/17/2024
Why does MIPS seem irrelevant to most wound care practitioners? A brief history of how we got here.
Journal of Clinical Pathways
09/17/2024
Adding pembrolizumab to adjuvant chemotherapy improves disease-free survival in women with high-risk endometrial cancer, particularly those with mismatch repair-deficient tumors, according to findings from the KEYNOTE-B-21 study presented at ESMO Congress.
Psych Congress Network
09/17/2024
Take a quick poll on your recent prescribing practices!
First Report Managed Care
09/17/2024
In July 2024, the Federal Trade Commission (FTC) published an interim report discussing the impact that pharmacy benefit managers (PBMs) have on the accessibility and affordability of drugs in the US. The report was issued as part of an ongoing investigation that began in 2022 under Section 6(b) of the FTC Act.
Vascular Disease Management, CardioVascular
09/17/2024
Watch as Dr. Michael Siah discusses 2 of his AMP 2024 presentations on ZilverPASS and DVA.
Oncology
09/17/2024
A panel of experts provided consensus recommendations on prevention, early detection, and management of adverse events potentially associated with selumetinib among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.
Vascular Disease Management, CardioVascular, Cath Lab Digest
09/17/2024
In this video, Dr. Zola N'Dandu discusses two of his AMP 2024 presentations.
Podiatry Today
09/17/2024
The authors present a rare case of fibroma of tendon sheath at the anterior ankle joint arising from the tibialis anterior in a 90-year-old male.
Oncology
09/17/2024
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and allogeneic hematopoietic cell transplantation.
EP Lab Digest
09/17/2024
Boston Scientific Corporation has received U.S. FDA approval to expand the indication for current-generation INGEVITY™+ Pacing Leads to include conduction system pacing and sensing of the left bundle branch area when connected to a single- or dual-chamber pacemaker.
Oncology
09/17/2024
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, Vascular Disease Management, EP Lab Digest
Calling Clinicians: Dartmouth Health Announces Launch of Medical Device Innovations Training Program
09/17/2024
"The medical device ecosystem needs active clinicians to guide the development process at companies and regulatory agencies," says Aaron V. Kaplan, MD, FACC, FNAI. “This program will provide scholars with a deep understanding of the medical device development process."
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
09/17/2024
HyperVue is the first intravascular imaging technology to combine two important imaging technologies, DeepOCT and NIRS, while optimizing for image quality and procedural efficiency in the cath lab, including no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and the most comprehensive AI-driven workflow and image analysis offering.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
09/17/2024
Based on data from a national clinical trial led by Children’s Hospital Los Angeles, the FDA approved the Minima stent for neonates, infants, and young children with aortic coarctation or branch pulmonary artery stenosis.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, Vascular Disease Management
09/17/2024
“LumiGuide unlocks the color visualization of wires, catheters, and patient anatomies in 3D from any angle, including simultaneous angles to generate ‘virtual biplane’ images. Combined with device navigation viewed from angles physically unachievable using conventional C-arm systems, it has already been shown to improve workflows, reduce procedure times, and decrease patient and staff radiation dose," said Dr. Atul Gupta.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
